Melatonin Protects Against Diabetic Kidney Disease via the SIRT1 / NLRP3 Signalling Pathway
Nephrology · 2025
DOI: 10.1111/nep.70073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology, 2025. Verfasst von Yaping Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Second Hospital of Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Melatonin, NLR Family, Pyrin Domain-Containing 3 Protein, Sirtuin 1, Diabetic Nephropathies. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: the Natural Science Foundation of Shandong Province, Joint Fund of the National Natural Science Foundation of China, the National Key R&D Program of China.
Abstract (Originalsprache)
Aim
Diabetic kidney disease (DKD) is a leading cause of end‐stage renal disease. Melatonin, a hormone with anti‐oxidative and anti‐inflammatory properties, has demonstrated potential in mitigating diabetic complications; however, its specific effects and mechanisms in DKD remain unclear. This study aimed to investigate the protective effects of melatonin on podocyte injury and renal damage in DKD and to elucidate its underlying mechanisms.
Methods
In vitro, podocytes were exposed to high glucose (HG) and advanced glycation end products (AGEs) to simulate a diabetic environment. The effects of melatonin on podocyte viability, cytoskeletal organisation, oxidative stress markers (MDA, SOD, CAT, and GSH), and NLRP3 signalling activation were assessed. In vivo, a DKD mouse model was treated with melatonin, and renal function, histopathology, oxidative stress, and inflammation were evaluated. The role of SIRT1 in mediating the effects of melatonin was also investigated.
Results
Melatonin improved podocyte viability, alleviated cytoskeletal disorganisation, reduced oxidative stress (decreased MDA, increased SOD, CAT, and GSH), and inhibited activation of the NLRP3 signalling pathway in podocytes and renal tissues. In DKD mice, melatonin reduced proteinuria, improved renal histopathology, and suppressed NLRP3‐mediated inflammation. Mechanistically, melatonin upregulated SIRT1 expression, which inhibited NLRP3 activation and downstream inflammatory responses.
Conclusion
Melatonin protects against DKD by enhancing podocyte viability, reducing oxidative stress, and suppressing NLRP3‐mediated inflammation through SIRT1 upregulation. These findings highlight the potential of melatonin as a therapeutic agent for DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, The Second Hospital of Shandong University, Jinan, China.
- Department of Pathology, The Second Hospital of Shandong University, Jinan, China.
ORCID-Profile: Gang Liu
Förderung
- the Natural Science Foundation of Shandong Province
- Joint Fund of the National Natural Science Foundation of China
- the National Key R&D Program of China
- Natural Science Foundation of Shandong Province
- National Key Research and Development Program of China
Zitieren
APA
Zhang, Y., Wang, Y., Yang, J., & Liu, G. (2025). Melatonin Protects Against Diabetic Kidney Disease via the SIRT1 / NLRP3 Signalling Pathway. Nephrology. https://doi.org/10.1111/nep.70073
Vancouver
Zhang Y, Wang Y, Yang J, Liu G. Melatonin Protects Against Diabetic Kidney Disease via the SIRT1 / NLRP3 Signalling Pathway. Nephrology. 2025. doi:10.1111/nep.70073
BibTeX
@article{Zhang2025,
author = {Zhang, Yaping and Wang, Yinghui and Yang, Jingyan and Liu, Gang},
title = {Melatonin Protects Against Diabetic Kidney Disease via the SIRT1 / NLRP3 Signalling Pathway},
journal = {Nephrology},
year = {2025},
doi = {10.1111/nep.70073}
}
EUVIMED